Value of new drugs should be evaluated based on efficacy
By Hwang, Byung-woo | translator Kang, Shin-Kook
24.08.27 05:59:23
가나다라
0
New standard for the flexible application of the ICER threshold was established...Specifies the innovativeness of new drugs
Raises expectations on the reimbursement of treatments that have been difficult to set a price due to unclear cost-effectiveness... How the government sets the ICER range will be key
KRPIA emphasizes the government’s flexible approach based on case studies of major countries that apply ICER for innovative new drugs
With the proportion of new drugs being introduced into Korea rising and the number of homegrown new drugs increasing, the need for a drug pricing policy that recognizes the value of these new drugs has been growing.
Recognizing the value of new drugs can lead to a virtuous cycle that drives profits and motivation for subsequent research and development (R&D) in the industry.
The 'Measure to Improve the Drug Pricing System to Reflect the Innovative Value of New Drugs' being discussed in this context has raised industry expectations, promising improved access
Hwang, Byung-woo(tuai@dailypharm.com)
If you want to see the full article, please JOIN US (click)